Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Moderna, Inc.
FDA advisors will vote 28 June on whether an Omicron component should be included in new COVID-19 booster vaccines. Following WHO recommendations, the FDA may no longer also be looking to update the primary vaccine series at this time.
The bivalent vaccine is likely to get regulatory support, along with government contracts, but competitors, notably Moderna, will also step into the ring.
In Vivo spoke with two company creators working in the biotech industry about their strategies for seeking new science and their funding philosophy when building the biotechs of tomorrow.
Panel expects to review five respiratory syncytial virus vaccines and vote on one or two of them in June 2023 and others four months later. Sanofi presents results of three clinical trials of its monoclonal antibody nirsevimab, which is on track to be the second RSV prophylaxis for infants.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- Caperna LLC
- Moderna Therapeutics, Inc.
- Moderna LLC
- Newco LS18, Inc.